• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Chennai, Jan. 23

Orchid Chemicals & Pharmaceuticals has announced that its Betalactam Active Pharmaceutical Ingredient (API) facility located in Aurangabad has been approved by the UK regulator, Medicines and Healthcare products Regulatory Agency (MHRA). The approval opens up the UK market for Orchid for Betalactam.

"The MHRA approval is an important step in the overall regulatory road map for and marketing of the Orchid's key betalactam product, Piperacillin - Tazobactam in the lucrative European markets," says the company's Managing Director, Mr K. Raghavendra Rao. The approval also signifies the first major international approval for the Aurangabad API manufacturing complex.

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
H&R Johnson to invest Rs 25 cr in R&D

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line